Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.